Lipella Pharmaceuticals has re-signed its manufacturing collaboration agreement with Cook MyoSite to support Chemistry, Manufacturing and Control (CMC) documentation supporting their clinical products LP-10 and LP-310.
Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, “We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC collaboration is increasingly valuable to Lipella as our clinical pipeline matures toward commercializable assets.”
Ryan Pruchnic, Managing Vice President of Cook MyoSite and a member of Lipella’s Board of Directors, added, “Our team is committed to ensuring high standards of safety, quality and execution, to support Lipella's clinical progress.”